Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, J Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz
The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower all-cause death. These benefits were observed in the context of substantial and persistent lowering of low-density lipoprotein cholesterol with alirocumab compared to that achieved with placebo. The safety profile of alirocumab was indistinguishable from matching placebo except for a ∼1...
April 24, 2024: European Heart Journal. Cardiovascular Pharmacotherapy